Hemolytic anemia is a type of condition that results from the premature destruction of red blood cells. In Protheragen's ongoing efforts to advance the treatment of hemolytic anemia, we are working to develop innovative therapies to improve its effective management. We have tailored solutions and strategically designed services to surpass your expectations.
Hemolytic anemia is an ensemble of disorders having in common the earlier than normal destruction of red blood cells (RBCs) resulting in reduced erythrocyte life expectancy, with an insufficient bone marrow compensation. Hemolytic anemia can be subdivided into two broad types: intrinsic (hereditary) and extrinsic (environmental), which have different causes, clinical features, and treatment options.
| Classification | Types | Disease Examples (Causes) |
|---|---|---|
| Intrinsic Hemolytic Anemias | Membrane Disorders |
|
| Enzyme Deficiencies |
|
|
| Hemoglobinopathies |
|
|
| Extrinsic Hemolytic Anemias | Immune-Mediated HA |
|
| Non-Immune |
|
The pathogenesis of hemolytic anemia includes either an internal defect of a red blood cell (RBC) or an external destructive factor responsible for the premature destruction of erythrocytes. Intrinsic causes include genetic mutations affecting erythrocyte membrane proteins, metabolic enzymes, or hemoglobin structure, which can impair the integrity and lifespan of erythrocytes. The external factors include the immune system's destruction of the cells, the physical and mechanical harm to the erythrocytes, or infections that injure the erythrocytes directly.
Fig.1 Mechanisms of hemolysis in warm antibody autoimmune hemolytic anemia. (Berentsen S, et al., 2019)
| Drug Names | Mechanism of Action | Targets | NCT Number | Phase |
|---|---|---|---|---|
| BIVV020 | Monoclonal antibody that inhibits C1s protease, blocking classical complement pathway activation | C1s | NCT04269551 | Approved |
| Daratumumab | Anti-CD38 monoclonal antibody depletes CD38+ plasma cells and pathogenic autoantibody-producing B-cells | CD38 | NCT05004259 | Phase II |
| HRS-5965 | Small-molecule inhibitor of complement factor B, preventing alternative pathway amplification | Factor B | NCT06684041 | Phase I |
| Parsaclisib | PI3Kδ inhibitor suppresses B-cell activation and autoantibody production | PI3Kδ | NCT03538041 | Phase II |
| Obexelimab | Bispecific antibody targeting CD19 and FcγRIIb, modulating B-cell activity and autoantibody responses | CD19/FcγRIIb | NCT05786573 | Phase III |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
At Protheragen, our unwavering commitment lies in delivering state-of-the-art diagnostic and therapeutic development services tailored specifically for hemolytic anemia. Our expertise is centered around the development of innovative therapies spanning multiple molecular classes, meticulously studied in intricately crafted disease models during the preclinical phase.
Protheragen is proud to deliver integrated preclinical services for hemolytic anemia which incorporates all facets of drug research, including pharmacodynamics (PD), pharmacokinetics (PK), and safety. All our research services are executed within the highest standards of quality and ethics to ensure that results are trustworthy. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
Myeloproliferative Disorders (MPDs)
Bone Marrow Failure Syndromes (BMFS)
